A critical role for p53 in the control of NF-κB-dependent gene expression in TLR4-stimulated dendritic cells exposed to genistein

Journal of Immunology

Volumn 178, Issue 8, 2007, Pages 5048-5057

  Dijsselbloem, Nathalie ^a   Goriely, Stanislas ^b   Albarani, Valentina ^b   Gerlo, Sarah ^a   Francoz, Sarah ^b,c   Marine, Jean Christophe ^c   Goldman, Michel ^b   Haegeman, Guy ^a   Vanden Berghe, Wim ^a,d  

^a GHENT UNIVERSITY   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d Molecular Biology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; ISOFLAVONE DERIVATIVE; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA BINDING; EMBRYO; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA ANALYSIS;

EID: 34247137556     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.8.5048     Document Type: Article

References (68)

1. King, A., and G. Young. 1999. Characteristics and occurrence of phenolic phytochemicals. J. Am. Diet. Assoc. 99: 213-218.
2. Liu, J., J. E. Burdette, H. Xu, C. Gu, R. B. van Breemen, K. P. Bhat, N. Booth, A. I. Constantinou, J. M. Pezzuto, H. H. Fong, et al. 2001. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J. Agric. Food Chem. 49: 2472-2479.
3. Dijsselbloem, N., W. Vanden Beighe, A. De Naeyer, and G. Haegeman. 2004. Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections: multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and antiinflammatory therapy. Biochem. Pharmacol. 68: 1171-1185.
4. Vanden Berghe, W., N. Dijsselbloem, L. Vermeulen, N. Ndlovu, E. Boone, and G. Haegeman. 2006. Attenuation of mitogen- and stress-activated protein kinase-1-driven nuclear factor-κB gene expression by soy isoflavones does not require estrogenic activity. Cancer Res. 66: 4852-4862.
5. Kang, J. S., Y. D. Yoon, M. H. Han, S. B. Han, K. Lee, M. R. Kang, E. Y. Moon, Y. J. Jeon, S. K. Park, and H. M. Kim. 2005. Estrogen receptor-independent inhibition of tumor necrosis factor-α gene expression by phytoestrogen equol is mediated by blocking nuclear factor-κB activation in mouse macrophages. Biochem. Pharmacol. 71: 136-143.
6. Gong, L., Y. Li, A. Nedeljkovic-Kurepa, and F. H. Sarkar. 2003. Inactivation of NF-κB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 22: 4702-4709.
7. Cooke, P. S., V. Selvaraj, and S. Yellayi. 2006. Genistein, estrogen receptors, and the acquired immune response. J. Nutr. 136: 704-708.
8. Mazzoni, A., and D. M. Segal. 2004. Controlling the Toll road to dendritic cell polarization. J. Leukocyte Biol. 75: 721-730.
9. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13: 251-276.
10. Swain, S. L., A. D. Weinberg, M. English, and G. Huston. 1990. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145: 3796-3806.
11. Diehl, S., and M. Rincon. 2002. The two faces of IL-6 on Th1/Th2 differentiation. MoI. Immunol. 39: 531-536.
12. + T cells. J. Exp. Med. 185: 461-469.
13. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
14. Hirano, T. 1998. Interleukin 6 and its receptor: ten years later. Int. Rev. Immunol. 16: 249-284.
15. Jones, S. A. 2005. Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol. 175: 3463-3468.
16. Nishimoto, N. 2005. Cytokine signal regulation and autoimmune disorders. Autoimmunity 38: 359-367.
17. Ishihara, K., and T. Hirano. 2002. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 13: 357-368.
18. Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2: 675-680.
19. Kawai, T., and S. Akira. 2006. TLR signaling. Cell Death Differ. 13: 816-825.
20. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18: 621-663.
21. Jacks, T., L. Remington, B. O. Williams, E. M. Schmitt, S. Halachmi, R. T. Bronson, and R. A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4: 1-7.
22. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rossner, F. Koch, N. Romani, and G. Schuler. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223: 77-92.
23. Latz, E., A. Visintin, E. Lien, K. A. Fitzgerald, B. G. Monks, E. A. Kurt-Jones, D. T. Golenbock, and T. Espevik. 2002. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the Toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 277: 47834-47843.
24. Vanden Berghe, W., S. Plaisance, E. Boone, K. De Bosscher, M. L. Schmitz, W. Fiers, and G. Haegeman. 1998. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-κB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273: 3285-3290.
25. Plaisance, S., W. Vanden Berghe, E. Boone, W. Fiers, and G. Haegeman. 1997. Recombination signal sequence binding protein Jκ is constitutively bound to the NF-κB site of the interleukin-6 promoter and acts as a negative regulatory factor. Mol. Cell. Biol. 17: 3733-3743.
26. Unger, T., M. M. Nau, S. Segal, and J. D. Minna. 1992. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11: 1383-1390.
27. Brummelkamp, T. R., R. Bernards, and R. Agami. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553.
28. Vermeulen, L., G. De Wilde, P. Van Damme, W. Vanden Berghe, and G. Haegeman. 2003. Transcriptional activation of the NF-κB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 22: 1313-1324.
29. De Bosscher, K., M. L. Schmitz, W. Vanden Berghe, S. Plaisance, W. Fiers, and G. Haegeman. 1997. Glucocorticoid-mediated repression of nuclear factor-κB-dependent transcription involves direct interference with transactivation. Proc. Natl. Acad. Sci. USA 94: 13504-13509.
30. Verdin, E., P. Paras, Jr., and C. Van Lint. 1993. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J. 12: 3249-3259.
31. Amenante, F., M. Merola, A. Furia, M. Tovey, and M. Palmieri. 1999. Interleukin-6 repression is associated with a distinctive chromatin structure of the gene. Nucleic Acids Res. 27: 4483-4490.
32. Lomvardas, S., and D. Thanos. 2002. Modifying gene expression programs by altering core promoter chromatin architecture. Cell 110: 261-271.
33. Smale, S. T., and A. G. Fisher. 2002. Chromatin structure and gene regulation in the immune system. Annu. Rev. Immunol. 20: 427-462.
34. Ramirez-Carrozzi, V. R., A. A. Nazarian, C. C. Li, S. L. Gore, R. Sridharan, A. N. Imbalzano, and S. T. Smale. 2006. Selective and antagonistic functions of SWI/SNF and Mi-2β nucleosome remodeling complexes during an inflammatory response. Genes Dev. 20: 282-296.
35. Vanden Berghe, W., M. N. Ndlovu, R. Hoya-Arias, N. Dijsselbloem, S. Gerlo, and G. Haegeman. 2006. Keeping up NF-κB appearances: epigenetic control of immunity or inflammation-triggered epigenetics. Biochem. Pharmacol. 72: 1114-1131.
36. Vanden Berghe, W., K. De Bosscher, E. Boone, S. Plaisance, and G. Haegeman. 1999. The nuclear factor-κB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J. Biol. Chem. 274: 32091-32098.
37. Li, Y., F. Ahmed, S. Ali, P. A. Philip, O. Kucuk, and F. H. Sarkar. 2005. Inactivation of nuclear factor κB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 65: 6934-6942.
38. 2/M cell cycle arrest. BMC Cancer 6: 107.
39. Wang, Z., Y. Zhang, S. Banerjee, Y. Li, and F. H. Sarkar. 2006. Inhibition of nuclear factor κB activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int. J. Cancer 118: 1930-1936.
40. Comalada, M., I. Ballester, E. Bailon, S. Sierra, J. Xaus, J. Galvez, F. S. Medina, and A. Zarzuelo. 2006. Inhibition of proinflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids: analysis of the structure-activity relationship. Biochem. Pharmacol. 72: 1010-1021.
41. Yoshimura, S., J. Bondeson, B. M. Foxwell, F. M. Brennan, and M. Feldmann. 2001. Effective antigen presentation by dendritic cells is NF-κB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int. Immunol. 13: 675-683.
42. Okura, A., H. Arakawa, H. Oka, T. Yoshinari, and Y. Monden. 1988. Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-ras-transformed NIH 3T3 cells. Biochem. Biophys. Res. Commun. 157: 183-189.
43. Markovits, J., C. Linassier, P. Fosse, J. Couprie, J. Pierre, A. Jacquemin-Sablon, J. M. Saucier, J. B. Le Pecq, and A. K. Larsen. 1989. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 49: 5111-5117.
44. Constantinou, A., R. Mehta, C. Runyan, K. Rao, A. Vaughan, and R. Moon. 1995. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J. Nat. Prod. 58: 217-225.
45. Ye, R., A. A. Goodarzi, E. U. Kurz, S. Saito, Y. Higashimoto, M. F. Lavin, E. Appella, C. W. Anderson, and S. P. Lees-Miller. 2004. The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst.). 3: 235-244.
46. waf1/cip1 and Wee1. Biochem. Pharmacol. 67: 717-726.
47. Sanceau, J., T. Kaisho, T. Hirano, and J. Wietzerbin. 1995. Triggering of the human interleukin-6 gene by interferon-γ and tumor necrosis factor-α in monocytic cells involves cooperation between interferon regulatory factor-1, NF κB, and Sp1 transcription factors. J. Biol. Chem. 270: 27920-27931.
48. Kang, S. H., D. A. Brown, I. Kitajima, X. Xu, O. Heidenreich, S. Gryaznov, and M. Nerenberg. 1996. Binding and functional effects of transcriptional factor Sp1 on the murine interleukin-6 promoter. J. Biol. Chem. 271: 7330-7335.
49. Webster, G. A., and N. D. Perkins. 1999. Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 19: 3485-3495.
50. Komarova, E. A., V. Krivokrysenko, K. Wang, N. Neznanov, M. V. Chernov, P. G. Komarov, M. L. Brennan, T. V. Golovkina, O. W. Rokhlin, D. V. Kuprash, et al. 2005. p53 is a suppressor of inflammatory response in mice. FASEB J. 19: 1030-1032.
51. Alarcon-Vargas, D., and Z. Ronai. 2002. p53-Mdm2: the affair that never ends. Carcinogenesis 23: 541-547.
52. Li, M., Z. Zhang, D. L. Hill, X. Chen, H. Wang, and R. Zhang. 2005. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res. 65: 8200-8208.
53. Zheng, S. J., S. E. Lamhamedi-Cherradi, P. Wang, L. Xu, and Y. H. Chen. 2005. Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 54: 1423-1428.
54. Yamanishi, Y., D. L. Boyle, M. J. Pinkoski, A. Mahboubi, T. Lin, Z. Man, N. J. Zvaifler, D. R. Green, and G. S. Firestein. 2002. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am. J. Pathol. 160: 123-130.
55. Angelo, L. S., M. Talpaz, and R. Kurzrock. 2002. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res. 62: 932-940.
56. Wadgaonkar, R., K. M. Phelps, Z. Haque, A. J. Williams, E. S. Silverman, and T. Collins. 1999. CREB-binding protein is a nuclear integrator of nuclear factor-κB and p53 signaling. J. Biol. Chem. 274: 1879-1882.
57. Ravi, R., B. Mookerjee, Y. van Hensbergen, G. C. Bedi, A. Giordano, W. S. El-Deiry, E. J. Fuchs, and A. Bedi. 1998. p53-mediated repression of nuclear factor-κB RelA via the transcriptional integrator p300. Cancer Res. 58: 4531-4536.
58. Shao, J., T. Fujiwara, Y. Kadowaki, T. Fukazawa, T. Waku, T. Itoshima, T. Yamatsuji, M. Nishizaki, J. A. Roth, and N. Tanaka. 2000. Overexpression of the wild-type p53 gene inhibits NF-κB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 19: 726-736.
59. Jeong, S. J., M. Radonovich, J. N. Brady, and C. A. Pise-Masison. 2004. HTLV-1 Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood 104: 1490-1497.
60. Ikeda, A., X. Sun, Y. Li, Y. Zhang, R. Eckner, T. S. Doi, T. Takahashi, Y. Obata, K. Yoshioka, and K. Yamamoto. 2000. p300/CBP-dependent and -independent transcriptional interference between NF-κB RelA and p53. Biochem. Biophys. Res. Commun. 272: 375-379.
61. Feng, Z., L. Kachnic, J. Zhang, S. N. Powell, and F. Xia. 2004. DNA damage induces p53-dependent BRCA1 nuclear export. J. Biol. Chem. 279: 28574-28584.
62. Feldherr, C. M., D. Akin, and R. J. Cohen. 2001. Regulation of functional nuclear pore size in fibroblasts. J. Cell Sci. 114: 4621-4627.
63. Margulies, L., and P. B. Sehgal. 1993. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBPβ (NF-IL6) activity by p53 species. J. Biol. Chem. 268: 15096-15100.
64. Asschert, J. G., E. G. De Vries, S. De Jong, S. Withoff, and E. Vellenga. 1999. Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: involvement of AP-1. Int. J. Cancer 81: 236-242.
65. Sanjabi, S., A. Hoffmann, H. C. Liou, D. Baltimore, and S. T. Smale. 2000. Selective requirement for c-Rel during IL-12 p40 gene induction in macrophages. Proc. Natl. Acad. Sci. USA 97: 12705-12710.
66. + dendritic cells by specifically inducing p35 gene transcription. J. Exp. Med. 194: 1021-1032.
67. Goriely, S., C. Van Lint, R. Dadkhah, M. Libin, D. De Wit, D. Demonte, F. Willems, and M. Goldman. 2004. A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. J. Exp. Med. 199: 1011-1016.
68. Vassilev, L. T. 2004. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3: 419-421.